Navigation Links
Icahn Asks Amylin to Allow Discussions With Eastbourne
Date:4/23/2009

NEW YORK, April 23 /PRNewswire/ -- Carl Icahn announced today that he had sent the following letter to James Wilson, Lead Independent Director of Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN).

                                        April 23, 2009

    Mr. James Wilson
    Lead Independent Director
    Amylin Pharmaceuticals, Inc.
    9360 Towne Centre Drive
    San Diego, CA  92121

    Dear Jim:

    If you are really serious about settling what you consider a debilitating
    proxy contest, I believe it is mandatory for you to take the necessary
    action to allow Eastbourne and myself to talk without the threat of your
    poison pill and Section 203 preventing these discussions.  It is almost
    absurd that I and Eastbourne, separately, have had to ask you a number of
    times during last week and the week before to get permission to have these
    talks.  As I have said, even in a dictatorship parties that disagree with
    the ruling regime are allowed to talk to each other.  But not at Amylin.

    I sincerely believe that as a result of these discussions and subsequent
    discussions among the three of us, there will be enough common ground to
    resolve the matter.  What exactly are you afraid of?  The alternative is
    for the Company and its stockholders to continue to be distracted because
    of the inexplicable intransigence of the current Board which continues to
    evidence itself in so many ways, e.g. the poison pill, the poison puts,
    and the failure to heed the views of your co-founder, Howard E. Greene,
    Jr., regarding Joseph Cook's board seat.

    I look forward to your prompt response.

                                        Sincerely,

                                        Carl Icahn

SECURITY HOLDERS ARE ADVISED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS RELATED TO THE SOLICITATION OF PROXIES BY CARL C. ICAHN, DR. ALEXANDER J. DENNER, DR. THOMAS F. DEUEL, MR. JULES HAIMOVITZ, DR. PETER LIEBERT, DR. DAVID SIDRANSKY, MR. MAYU SRIS, MR. JEFFREY MECKLER, DR. ERIC ENDE, ICAHN Partners LP, Icahn Partners Master Fund LP, Icahn Partners Master Fund II LP, Icahn Partners Master Fund III LP, Icahn Enterprises G.P. Inc., Icahn Enterprises Holdings L.P., IPH GP LLC, Icahn Capital L.P., Icahn Onshore LP, Icahn Offshore LP, Beckton Corp., AND CERTAIN OF THEIR RESPECTIVE AFFILIATES FROM THE STOCKHOLDERS OF AMYLIN PHARMACEUTICALS, INC, FOR USE AT ITS ANNUAL MEETING WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING INFORMATION RELATING TO THE PARTICIPANTS IN ANY SUCH PROXY SOLICITATION. WHEN COMPLETED, A DEFINITIVE PROXY STATEMENT AND A FORM OF PROXY WILL BE AVAILABLE TO STOCKHOLDERS OF AMYLIN PHARMACEUTICALS, INC. FROM THE PARTICIPANTS AT NO CHARGE AND WILL ALSO BE AVAILABLE AT NO CHARGE AT THE SECURITIES AND EXCHANGE COMMISSION'S WEBSITE AT HTTP://WWW.SEC.GOV.

INFORMATION RELATING TO THE PARTICIPANTS IN THIS PROXY SOLICITATION IS CONTAINED IN SCHEDULE 14A FILED BY THE PARTICIPANTS WITH THE SECURITIES AND EXCHANGE COMMISSION, WHICH DOCUMENTS ARE AVAILABLE AT NO CHARGE AT THE SECURITIES AND EXCHANGE COMMISSION'S WEBSITE AT HTTP://WWW.SEC.GOV.


'/>"/>
SOURCE Carl Icahn
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Icahn Responds to Cornelius
2. Icahn Confirms Intention to Nominate Three Directors at Biogen
3. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
4. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
5. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
6. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
7. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
8. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
9. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
10. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
11. Amylin Pharmaceuticals Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology:
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):